265 related articles for article (PubMed ID: 31098989)
1. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
[TBL] [Abstract][Full Text] [Related]
2. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
3. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
[TBL] [Abstract][Full Text] [Related]
4. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
Lee YR; Baker NT
Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
6. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Wunderink RG; Giamarellos-Bourboulis EJ; Rahav G; Mathers AJ; Bassetti M; Vazquez J; Cornely OA; Solomkin J; Bhowmick T; Bishara J; Daikos GL; Felton T; Furst MJL; Kwak EJ; Menichetti F; Oren I; Alexander EL; Griffith D; Lomovskaya O; Loutit J; Zhang S; Dudley MN; Kaye KS
Infect Dis Ther; 2018 Dec; 7(4):439-455. PubMed ID: 30270406
[TBL] [Abstract][Full Text] [Related]
7. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination.
Novelli A; Del Giacomo P; Rossolini GM; Tumbarello M
Expert Rev Anti Infect Ther; 2020 Jul; 18(7):643-655. PubMed ID: 32297801
[TBL] [Abstract][Full Text] [Related]
8. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
[TBL] [Abstract][Full Text] [Related]
9. Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.
Weiss WJ; Pulse ME; Nguyen P; Peterson K; Silva J; Simecka JW; Valtierra D; Sabet M; Griffith DC
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038270
[TBL] [Abstract][Full Text] [Related]
10. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
Wenzler E; Scoble PJ
Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
[TBL] [Abstract][Full Text] [Related]
11. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Patel TS; Pogue JM; Mills JP; Kaye KS
Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
[TBL] [Abstract][Full Text] [Related]
12. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
Dhillon S
Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
[TBL] [Abstract][Full Text] [Related]
13. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Albin OR; Patel TS; Kaye KS
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
[TBL] [Abstract][Full Text] [Related]
14. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
15. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
Shields RK; McCreary EK; Marini RV; Kline EG; Jones CE; Hao B; Chen L; Kreiswirth BN; Doi Y; Clancy CJ; Nguyen MH
Clin Infect Dis; 2020 Jul; 71(3):667-671. PubMed ID: 31738396
[TBL] [Abstract][Full Text] [Related]
16. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.
Cho JC; Zmarlicka MT; Shaeer KM; Pardo J
Ann Pharmacother; 2018 Aug; 52(8):769-779. PubMed ID: 29514462
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK.
Vlachaki I; Zinzi D; Falla E; Mantopoulos T; Guy H; Jandu J; Dodgson A
Eur J Health Econ; 2022 Apr; 23(3):537-549. PubMed ID: 34546484
[TBL] [Abstract][Full Text] [Related]
18. Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.
Pogue JM; Bonomo RA; Kaye KS
Clin Infect Dis; 2019 Jan; 68(3):519-524. PubMed ID: 30020449
[TBL] [Abstract][Full Text] [Related]
19. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
[TBL] [Abstract][Full Text] [Related]
20. Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections.
Lai CC; Chen CC; Tang HJ
J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31614430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
